Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial

NCT05556720 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

960

Enrollment

OTHER

Sponsor class

Conditions

HIV
Organ Transplantation
Lymphoma, Non-Hodgkin
Chronic Lymphocytic Leukemia
Multiple Myeloma
COVID-19 Vaccines

Interventions

BIOLOGICAL: Pfizer Bivalent COVID-19 Vaccine
BIOLOGICAL: Moderna Bivalent mRNA vaccine

Sponsor

Monash University

Collaborators

[object Object]
[object Object]